TERMINATION AND TRANSITION SERVICES AGREEMENTTermination and Transition Services Agreement • October 14th, 2022 • New York
Contract Type FiledOctober 14th, 2022 JurisdictionThis Termination and Transition Services Agreement (this “Agreement”) is made and entered into on August 15, 2022 (the “Execution Date”) by and among (a) IMMUNOMEDICS, INC., a company organized under the laws of the state of Delaware (“Immunomedics”) and a wholly-owned subsidiary of Gilead Sciences, Inc. (“Gilead”), (b) EVEREST MEDICINES II LIMITED, an exempt company organized under the laws of the Cayman Islands (“Everest Medicines II”), (c) EVEREST MEDICINES (SINGAPORE) PTE. LTD. (“Everest Singapore”, together with Everest Medicines II, “Everest”), and (d) solely with respect to Sections 1.1, 1.2 and 13.19, EVEREST MEDICINES LIMITED, an exempt company organized under the laws of the Cayman Islands (“Everest Parent”). Each of Immunomedics and Everest is referred to individually as a “Party” and collectively as the “Parties.”